Kardigan Files for IPO with Three Late-Stage Cardiovascular Programs Targeting Unmet Medical Needs
核心洞察
Kardigan (搜索), a clinical-stage cardiovascular therapeutics company founded by former MyoKardia (搜索) executives, has filed for an IPO on Nasdaq under ticker "KARD" with J.P. Morgan and other major banks as underwriters.
The company is developing three late-stage programs including danicamtiv for genetic dilated cardiomyopathy (搜索), ataciguat for calcific aortic valve stenosis (搜索), and tonlamarsen for acute severe hypertension (搜索) management.
Kardigan (搜索) has raised nearly $570 million to date, including a $254 million Series B round, with all three programs targeting topline data in the first half of 2027.
Kardigan (搜索), a clinical-stage precision cardiovascular therapeutics company founded by former MyoKardia (搜索) executives, has filed for an initial public offering on the Nasdaq Global Market under the ticker "KARD." The company, which was founded in 2023, is developing medicines that target the root causes of specific cardiovascular diseases where no approved treatments currently exist.
The IPO filing comes as Kardigan (搜索) advances three late-stage drug programs, all targeting topline data in the first half of 2027. J.P. Morgan, Jefferies, Leerink Partners and TD Cowen are acting as joint bookrunners for the offering.
Three Late-Stage Programs Address Unmet Medical Needs
Kardigan (搜索)'s lead asset, danicamtiv, was in-licensed from Bristol Myers Squibb (搜索) and represents a cardiac myosin (搜索) activator designed to strengthen heart muscle contractions. The drug is being evaluated in a Phase 2b/3 study called KINSHIP-DCM for patients with genetically driven dilated cardiomyopathy (搜索), a condition that weakens the heart and prevents adequate pumping of oxygenated blood throughout the body. Danicamtiv is designed to restore myosin function specifically in patients with MYH7 (搜索) and TTN (搜索) genetic variants.
The company's second program, ataciguat, targets calcific aortic valve stenosis (搜索) (CAVS), which affects approximately 3.3 million people in the United States with a 3% prevalence in those over 60 years old. Originally developed by Sanofi and Mayo Clinic, ataciguat works by targeting oxidized soluble guanylate cyclase (搜索) in valvular interstitial cells to blunt calcific remodeling. The drug is currently being studied in the Phase 2b KATALYST-AV trial.
Tonlamarsen, the third program, is a liver-directed antisense oligonucleotide in-licensed from Ionis Pharmaceuticals (搜索). The drug modulates hepatic angiotensinogen (搜索) to support safer, sustained blood pressure control and is being evaluated in the Phase 2 KARDINAL-ASH trial for post-hospitalization blood pressure management in acute severe hypertension (搜索).
Digital Platform Enhances Clinical Development
Kardigan (搜索)'s proprietary Prolaio platform integrates FDA-regulated digital tools and wearable data to continuously collect physiologic signals in real-world settings. The platform holds over 4 million hours of continuous physiologic data and features seven 510(k)-cleared algorithms. According to the company, this approach aims to make trials faster, smaller, and more informative compared to traditional cardiovascular outcomes trials that rely on infrequent in-office measurements.
The company's strategy focuses on well-defined patient populations, causal biology, and early regulatory engagement for functional endpoints, employing "near real-time continuous data collection" with smaller enrollments and quicker turnarounds.
Strong Financial Backing and Experienced Leadership
Kardigan (搜索) has raised almost $570 million as of March 31, with the sum growing significantly following the close of a $254 million Series B funding round last fall. The company's investors include Perceptive Advisors, ARCH Venture Partners, Sequoia Heritage, Fidelity Management & Research Company, and accounts advised by T. Rowe Price Investment Management.
The company is led by CEO Tassos Gianakakos, former CEO of MyoKardia (搜索), and Chief Medical Officer Jay Edelberg, M.D., Ph.D., a cardiologist and vascular biologist who previously served as CMO at MyoKardia. MyoKardia was acquired by Bristol Myers Squibb (搜索) for just north of $13 billion and discovered Camzyos, which has since become a blockbuster heart medication.
Financial Performance and Market Position
Running multiple mid- to late-stage studies has proven expensive for Kardigan (搜索). The company's research and development costs surged 80% last year to $153 million, while net operational losses more than doubled in 2025 to nearly $202 million. The company reported a net loss of $191.9 million for fiscal year 2025.
Kardigan (搜索) operates with 241 employees and approximately 139 consultants, with headquarters in Princeton, New Jersey, and offices and labs in South San Francisco, California. The company holds 20+ issued patents and conducts multi-country clinical trial sites.
The IPO filing comes amid a modest uptick in biotech IPOs, with this year's tally of 11 already matching the overall total seen in 2025. Market observers note that investors are increasingly interested in companies that have "derisked" key programs with compelling data from human trials, with nearly all of this year's IPO class having drugs in Phase 2 or 3 testing and raising $250 million or more through their offerings.